These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 28624436)

  • 1. Zonisamide inhibits monoamine oxidase and enhances motor performance and social activity.
    Uemura MT; Asano T; Hikawa R; Yamakado H; Takahashi R
    Neurosci Res; 2017 Nov; 124():25-32. PubMed ID: 28624436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of zonisamide on dopaminergic system.
    Okada M; Kaneko S; Hirano T; Mizuno K; Kondo T; Otani K; Fukushima Y
    Epilepsy Res; 1995 Nov; 22(3):193-205. PubMed ID: 8991786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel dopamine releasing response of an anti-convulsant agent with possible anti-Parkinson's activity.
    Gluck MR; Santana LA; Granson H; Yahr MD
    J Neural Transm (Vienna); 2004 Jun; 111(6):713-24. PubMed ID: 15168218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zonisamide increases dopamine turnover in the striatum of mice and common marmosets treated with MPTP.
    Yabe H; Choudhury ME; Kubo M; Nishikawa N; Nagai M; Nomoto M
    J Pharmacol Sci; 2009 May; 110(1):64-8. PubMed ID: 19403994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease.
    Murata M
    Curr Pharm Des; 2004; 10(6):687-93. PubMed ID: 14965331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zonisamide has beneficial effects on Parkinson's disease patients.
    Murata M; Horiuchi E; Kanazawa I
    Neurosci Res; 2001 Dec; 41(4):397-9. PubMed ID: 11755227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Discovery of an antiparkinsonian drug: zonisamide].
    Murata M
    Rinsho Shinkeigaku; 2010 Nov; 50(11):780-2. PubMed ID: 21921440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preventing effects of a novel anti-parkinsonian agent zonisamide on dopamine quinone formation.
    Asanuma M; Miyazaki I; Diaz-Corrales FJ; Miyoshi K; Ogawa N; Murata M
    Neurosci Res; 2008 Jan; 60(1):106-13. PubMed ID: 18022268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile.
    Aubin N; Barneoud P; Carter C; Caille D; Sontag N; Marc C; Lolivier J; Gardes A; Perron C; Le Kim A; Charieras T; Pandini M; Burnier P; Puech F; Jegham S; George P; Scatton B; Curet O
    J Pharmacol Exp Ther; 2004 Sep; 310(3):1171-82. PubMed ID: 15178694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zonisamide enhances delta receptor-associated neurotransmitter release in striato-pallidal pathway.
    Yamamura S; Ohoyama K; Nagase H; Okada M
    Neuropharmacology; 2009 Sep; 57(3):322-31. PubMed ID: 19482038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The discovery of an antiparkinsonian drug, zonisamide].
    Murata M
    Rinsho Shinkeigaku; 2010 Feb; 50(2):67-73. PubMed ID: 20196486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adh1 and Adh1/4 knockout mice as possible rodent models for presymptomatic Parkinson's disease.
    Anvret A; Ran C; Westerlund M; Gellhaar S; Lindqvist E; Pernold K; Lundströmer K; Duester G; Felder MR; Galter D; Belin AC
    Behav Brain Res; 2012 Feb; 227(1):252-7. PubMed ID: 22079585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroprotective effects of zonisamide target astrocyte.
    Asanuma M; Miyazaki I; Diaz-Corrales FJ; Kimoto N; Kikkawa Y; Takeshima M; Miyoshi K; Murata M
    Ann Neurol; 2010 Feb; 67(2):239-49. PubMed ID: 20225289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Administration of zonisamide in three cases of dementia with Lewy bodies.
    Odawara T; Shiozaki K; Togo T; Hirayasu Y
    Psychiatry Clin Neurosci; 2010 Jun; 64(3):327-9. PubMed ID: 20408991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The subthalamic activity and striatal monoamine are modulated by subthalamic stimulation.
    Yamamoto T; Uchiyama T; Sakakibara R; Taniguchi J; Kuwabara S
    Neuroscience; 2014 Feb; 259():43-52. PubMed ID: 24291727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1-[2-(4-Benzyloxyphenoxy)Ethyl]Imidazole inhibits monoamine oxidase B and protects against neuronal loss and behavioral impairment in rodent models of Parkinson's disease.
    Chung JY; Lee JW; Ryu CH; Min HK; Yoon YJ; Lim MJ; Park CH
    J Neurosci Res; 2015 Aug; 93(8):1267-78. PubMed ID: 25711470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-inflammatory properties rather than anti-oxidant capability is the major mechanism of neuroprotection by sodium salicylate in a chronic rotenone model of Parkinson's disease.
    Thakur P; Nehru B
    Neuroscience; 2013 Feb; 231():420-31. PubMed ID: 23159314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased behavioral response to intranigrally administered GABAA agonist muscimol in the lactacystin model of Parkinson's disease may result from partial lesion of nigral non-dopamine neurons: comparison to the classical neurotoxin 6-OHDA.
    Konieczny J; Czarnecka A; Kamińska K; Lenda T; Nowak P
    Behav Brain Res; 2015 Apr; 283():203-14. PubMed ID: 25655509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zonisamide for the treatment of Parkinson's disease.
    Miwa H
    Expert Rev Neurother; 2007 Sep; 7(9):1077-83. PubMed ID: 17868006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential degradation of motor deficits during gradual dopamine depletion with 6-hydroxydopamine in mice.
    Willard AM; Bouchard RS; Gittis AH
    Neuroscience; 2015 Aug; 301():254-67. PubMed ID: 26067595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.